SIFI is currently evaluating various options for the commercialization of Akantior (polihexanide) globally, including potential out-license agreements outside its core markets
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
Data integrity early warning system assists pharmaceutical clients in proactively identifying and managing data integrity challenges in line with regulatory guidelines
The guidance also urges companies to act quickly to initiate a recall when public health is at risk and to do so prior to completing an investigation into the cause of the problem
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Covaxin is not approved in the USA for any age group
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Subscribe To Our Newsletter & Stay Updated
